Want to join the conversation?
$ABBV said Imbruvica is tracking in line to slightly ahead of its expectations, following its approval for first-line use in chronic lymphocytic leukemia. Imbruvica has achieved the number one market share position in all approved disease indications in second-line and second-line plus treatment.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?